cagrilintide + Samaglutide

The combination of semaglutide and cagrilintide is associated with significant reductions in weight among adults with overweight or obesity who do not have diabetes, according to study results published in The New England Journal of Medicine.

Cagrilintide is a long-acting, human amylin that affects appetite regulation via direct effects in the brain.

Researchers conducted a phase 3a, multicenter, double-blind, placebo- and active-controlled trial, the REDEFINE 1 study (ClinicalTrials.gov Identifier: NCT05567796), across 22 countries. For 68 weeks, adults (N=3417) with a BMI 30 kg/m² or higher or 27 kg/m² or higher combined with obesity-related complications were randomly assigned 21:3:3:7 to receive weekly subcutaneous injections of 2.4 mg semaglutide and 2.4 mg cagrilintide (n=2108), 2.4 mg semaglutide and placebo (n=302), 2.4 mg cagrilintide and placebo (n=302), or double placebo (n=705). All participants also received a lifestyle intervention. Both semaglutide and cagrilintide were titrated up from initial doses of 0.25 mg. The coprimary endpoints were the relative change in body weight at 68 weeks and a reduction of at least 5% from baseline